Results 231 to 240 of about 44,899 (264)

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6

dmdi, 2013
Abstract The cytochrome P450 2D6 (CYP2D6) belongs to a group of CYPs considered of utmost importance in the metabolism of xenobiotics. Despite being of only minor abundance in the liver, it is involved in the clearance of >25% of marketed drugs.
openaire   +2 more sources

CYP2D6 Genotype and Adjuvant Tamoxifen

Clinical Pharmacology & Therapeutics, 2014
A study by Province et al. for the International Tamoxifen Pharmacogenomics Consortium (ITPC) appeared in a recent issue of this journal.1 In addition to discussing this study and biomarker studies in general, I provide an overall assessment of the evidence regarding testing for CYP2D6 in making clinical decisions regarding the use of tamoxifen in ...
openaire   +2 more sources

Genetic Polymorphism in Cytochrome P450 2D6 (CYP2D6): Population Distribution of CYP2D6 Activity

Journal of Toxicology and Environmental Health, Part B, 2009
Cytochrome P-450 2D6 (CYP2D6) is involved in the metabolism of many therapeutic drugs even though the enzyme represents a small proportion of the total CYP content of human liver. In vivo phenotyping with probe drug substrates such as debrisoquine and dextromethorphan showed a clear separation between poor metabolizers (PM) and extensive metabolizers ...
Patricia, Neafsey, Gary, Ginsberg, Dale, Hattis, Babasaheb, Sonawane   +3 more
openaire   +2 more sources

MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers

European Journal of Clinical Pharmacology, 2005
(CYP)isoform 2D6 [2]. HHMA is further metabolised to 4-hydroxy, 3-methoxymethamphetamine (HMMA) bycatechol- O-methyltransferase (COMT). HMMA in-duces vasopressin secretion to a higher extent thanMDMA and has been postulated to contribute to hyp-onatraemia observed in some MDMA acute intoxica-tions [4].
Rafael, de la Torre, Magí, Farré, Brian O, Mathúna, Pere N, Roset, Neus, Pizarro, Mireia, Segura, Marta, Torrens, Jordi, Ortuño, Mitona, Pujadas, Jordi, Camí   +9 more
openaire   +2 more sources

CYP2D6 genetic variation in Ugandans

European Journal of Clinical Pharmacology, 2021
Jun Miura, Celestino Obua, Catherine Abbo, Tomonori Tateishi, Sunao Kaneko   +4 more
openaire   +2 more sources

CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10

Pharmacogenetics, 2000
Y, Nishida, T, Fukuda, I, Yamamoto, J, Azuma   +3 more
openaire   +2 more sources

CYP2D6-Tamoxifen

Der Gynäkologe, 2010
H. Brauch, W. Schroth
openaire   +1 more source

Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide

Archives of Pharmacal Research, 2020
Jung-Woo Bae, Eui Hyun Jung, Chang-Ik Choi   +2 more
exaly  

CYP2D6 genotyping and codeine

Pediatric Anesthesia, 2008
openaire   +2 more sources

Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone

Archives of Pharmacal Research, 2022
Choon-Gon Jang, Seok-Yong Lee, Chang-Ik Choi   +2 more
exaly